Citizens Jmp Has Lowered Expectations for argenex (NASDAQ:ARGX) Stock Price

argenex (NASDAQ:ARGX) had its price target decreased by equities researchers at Citizens Jmp from $944.00 to $932.00 in a research report issued on Friday,Benzinga reports. The firm presently has a “market outperform” rating on the stock. Citizens Jmp’s price objective indicates a potential upside of 0.80% from the stock’s previous close.

A number of other research firms have also weighed in on ARGX. Bank of America raised their target price on argenex from $1,016.00 to $1,088.00 and gave the company a “buy” rating in a report on Thursday, July 2nd. Citigroup increased their price target on argenex from $1,152.00 to $1,182.00 and gave the company a “buy” rating in a research report on Tuesday. Oppenheimer dropped their price objective on argenex from $1,060.00 to $1,014.00 and set an “outperform” rating on the stock in a research note on Thursday, April 2nd. Wedbush reaffirmed an “outperform” rating and set a $1,000.00 price objective on shares of argenex in a report on Thursday, June 11th. Finally, Morgan Stanley upped their target price on shares of argenex from $1,170.00 to $1,180.00 and gave the stock an “overweight” rating in a research note on Wednesday, June 24th. Two analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, argenex presently has a consensus rating of “Moderate Buy” and a consensus price target of $1,042.00.

argenex Price Performance

ARGX opened at $924.60 on Friday. argenex has a fifty-two week low of $577.04 and a fifty-two week high of $953.58. The firm has a market capitalization of $57.84 billion, a PE ratio of 41.17, a P/E/G ratio of 1.05 and a beta of 0.45. The company’s 50-day moving average is $865.90 and its 200 day moving average is $814.39.

argenex (NASDAQ:ARGX) last released its quarterly earnings results on Tuesday, July 21st. The company reported $7.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.86 by $1.46. The business had revenue of $1.54 billion during the quarter, compared to the consensus estimate of $1.45 billion. argenex had a return on equity of 44.37% and a net margin of 31.31%. As a group, analysts expect that argenex will post 26.27 EPS for the current year.

Institutional Trading of argenex

Hedge funds have recently bought and sold shares of the business. Janus Henderson Group PLC grew its stake in argenex by 3.4% in the 1st quarter. Janus Henderson Group PLC now owns 2,541,732 shares of the company’s stock valued at $1,847,592,000 after purchasing an additional 83,568 shares during the period. M&T Bank Corp raised its stake in shares of argenex by 20,977.7% during the 4th quarter. M&T Bank Corp now owns 778,610 shares of the company’s stock worth $654,772,000 after purchasing an additional 774,916 shares during the period. Wellington Management Group LLP raised its stake in shares of argenex by 80.1% during the 3rd quarter. Wellington Management Group LLP now owns 729,986 shares of the company’s stock worth $538,408,000 after purchasing an additional 324,653 shares during the period. Morgan Stanley boosted its holdings in shares of argenex by 19.2% in the 4th quarter. Morgan Stanley now owns 518,852 shares of the company’s stock worth $436,331,000 after buying an additional 83,746 shares during the last quarter. Finally, Invesco Ltd. boosted its holdings in shares of argenex by 390.4% in the 4th quarter. Invesco Ltd. now owns 416,408 shares of the company’s stock worth $350,178,000 after buying an additional 331,489 shares during the last quarter. 60.32% of the stock is currently owned by institutional investors.

Key Stories Impacting argenex

Here are the key news stories impacting argenex this week:

• Positive Sentiment: argenex delivered Q2 results that beat expectations, with EPS of $7.32 versus $5.86 expected and revenue of $1.54 billion versus $1.45 billion expected, reinforcing the strength of its commercial execution. Earnings report and transcript
• Positive Sentiment: Vyvgart sales jumped sharply in the second quarter, with multiple reports citing roughly 60% growth, signaling continued momentum in the company’s lead franchise. Reuters article
• Positive Sentiment: Analysts turned more constructive after the report, with Guggenheim reiterating a Buy rating and other commentary suggesting the stock could rise on improving fundamentals and pipeline catalysts. Analyst upgrade article
• Neutral Sentiment: Management discussed upcoming pipeline readouts, including empasiprubart in MMN, which adds longer-term optionality but is still a development-stage catalyst rather than immediate earnings support. Seeking Alpha rating upgrade
• Neutral Sentiment: The company emphasized a strong balance sheet with about $3.6 billion in cash and minimal debt, supporting self-funded R&D and pipeline expansion. Business Insider report

argenex Company Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.